Oxidative damage in glutaric aciduria type I patients and the protective effects of L-carnitine treatment
Carregando...
Citações na Scopus
28
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
GUERREIRO, Gilian
FAVERZANI, Jessica
JACQUES, Carlos Eduardo Diaz
MARCHETTI, Desiree P.
SITTA, Angela
COELHO, Daniella de Moura
KAYSER, Aline
MANFREDINI, Vanusa
Citação
JOURNAL OF CELLULAR BIOCHEMISTRY, v.119, n.12, p.10021-10032, 2018
Resumo
The deficiency of the enzyme glutaryl-CoA dehydrogenase, known as glutaric acidemia type I (GA-I), leads to the accumulation of glutaric acid (GA) and glutarilcarnitine (C5DC) in the tissues and body fluids, unleashing important neurotoxic effects. l-carnitine (l-car) is recommended for the treatment of GA-I, aiming to induce the excretion of toxic metabolites. l-car has also demonstrated an important role as antioxidant and anti-inflammatory in some neurometabolic diseases. This study evaluated GA-I patients at diagnosis moment and treated the oxidative damage to lipids, proteins, and the inflammatory profile, as well as in vivo and in vitro DNA damage, reactive nitrogen species (RNS), and antioxidant capacity, verifying if the actual treatment with l-car (100 mg kg(-1) day(-1)) is able to protect the organism against these processes. Significant increases of GA and C5DC were observed in GA-I patients. A deficiency of carnitine in patients before the supplementation was found. GA-I patients presented significantly increased levels of isoprostanes, di-tyrosine, urinary oxidized guanine species, and the RNS, as well as a reduced antioxidant capacity. The l-car supplementation induced beneficial effects reducing these biomarkers levels and increasing the antioxidant capacity. GA, in three different concentrations, significantly induced DNA damage in vitro, and the l-car was able to prevent this damage. Significant increases of pro-inflammatory cytokines IL-6, IL-8, GM-CSF, and TNF-alpha were shown in patients. Thus, the beneficial effects of l-car presented in the treatment of GA-I are due not only by increasing the excretion of accumulated toxic metabolites, but also by preventing oxidative damage.
Palavras-chave
DNA damage, glutaric aciduria type I, glutaryl-CoA dehydrogenase, inflammation, L-carnitine, oxidative stress
Referências
- Amaral AU, 2012, MOL GENET METAB, V107, P81, DOI 10.1016/j.ymgme.2012.04.015
- Amarala AU, 2015, BRAIN RES, V1620, P116, DOI 10.1016/j.brainres.2015.05.013
- Bahl J, 1989, PHARMACOLOGY, V337, P118
- Rodrigues DGB, 2017, TOXICOL IN VITRO, V42, P47, DOI 10.1016/j.tiv.2017.04.006
- Biancini GB, 2017, NEPHROLOGY, V22, P490, DOI 10.1111/nep.12977
- Bourdon E, 2001, ANTIOXID REDOX SIGN, V3, P293, DOI 10.1089/152308601300185241
- Burlina AP, 2004, J INHERIT METAB DIS, V27, P911, DOI 10.1023/B:BOLI.0000045776.50573.52
- Chace DH, 1997, CLIN CHEM, V43, P2106
- Colin-Gonzalez AL, 2015, NEUROSCIENCE, V308, P64, DOI 10.1016/j.neuroscience.2015.09.002
- Cooke MS, 2006, CLIN CHIM ACTA, V365, P30, DOI 10.1016/j.cca.2005.09.009
- Deon M, 2015, INT J DEV NEUROSCI, V47, P259, DOI 10.1016/j.ijdevneu.2015.10.001
- Deon M, 2015, METAB BRAIN DIS, V30, P925, DOI 10.1007/s11011-015-9649-1
- Farooqui AA, 2010, MOL NEUROBIOL, V41, P267, DOI 10.1007/s12035-009-8091-y
- Ferreira GC, 2007, INT J DEV NEUROSCI, V25, P391, DOI 10.1016/j.ijdevneu.2007.05.009
- Galic MA, 2012, FRONT NEUROENDOCRIN, V33, P116, DOI 10.1016/j.yfrne.2011.12.002
- Gokmen-Ozel H, 2012, J HUM NUTR DIET, V25, P514, DOI 10.1111/j.1365-277X.2012.01269.x
- GOODMAN SI, 1977, J PEDIATR-US, V90, P746, DOI 10.1016/S0022-3476(77)81240-7
- Goodman SI, 2001, METABOLIC MOL BASES
- Guerreiro G, 2015, INT J DEV NEUROSCI, V42, P10, DOI 10.1016/j.ijdevneu.2015.02.003
- Halliwell B, 2001, FREE RADICALS BIOL M
- Heringer J, 2010, ANN NEUROL, V68, P743, DOI 10.1002/ana.22095
- Kirschbaum B, 2002, CLIN NEPHROL, V58, P344
- Kolker S, 2000, J INHERIT METAB DIS, V23, P359, DOI 10.1023/A:1005683314525
- Kolker S, 2004, ANN NEUROL, V55, P7, DOI 10.1002/ana.10784
- Kolker S, 2003, NEUROLOGY, V60, P1399, DOI 10.1212/WNL.60.8.1399
- Kolker S, 2001, PEDIATR RES, V50, P76
- Kolodziejczyk J, 2011, NUTRITION, V27, P693, DOI 10.1016/j.nut.2010.06.009
- Latini A, 2007, CELL MOL NEUROBIOL, V27, P423, DOI 10.1007/s10571-006-9134-9
- Leipnitz G, 2005, INT J DEV NEUROSCI, V23, P695, DOI 10.1016/j.ijdevneu.2005.08.004
- Lugrin J, 2014, BIOL CHEM, V395, P203, DOI 10.1515/hsz-2013-0241
- Couce ML, 2013, EUR J PAEDIATR NEURO, V17, P383, DOI 10.1016/j.ejpn.2013.01.003
- Magni DV, 2009, INT J DEV NEUROSCI, V27, P65, DOI 10.1016/j.ijdevneu.2008.09.004
- Mello MD, 2015, MOL CELL BIOCHEM, V402, P149, DOI 10.1007/s11010-014-2322-x
- Mescka CP, 2016, MOL NEUROBIOL, V53, P6007, DOI 10.1007/s12035-015-9500-z
- Mescka CP, 2015, METAB BRAIN DIS, V30, P1167, DOI 10.1007/s11011-015-9686-9
- Nunes J, 2013, NEURORADIOL J, V26, P155, DOI 10.1177/197140091302600204
- Rodrigues MDN, 2017, MOL NEUROBIOL, V54, P4795, DOI 10.1007/s12035-016-0023-z
- Rodrigues MDN, 2015, J NEUROL SCI, V359, P133, DOI 10.1016/j.jns.2015.10.043
- Pfeil J, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-167
- Ribas GS, 2012, CELL MOL NEUROBIOL, V32, P77, DOI 10.1007/s10571-011-9736-8
- Rosales-Corral S, 2010, ANTIOXID REDOX SIGN, V13, P193, DOI 10.1089/ars.2009.2629
- Scriver C.R., 2001, METABOLIC MOL BASES
- Seminotti B, 2016, MOL NEUROBIOL, V53, P6459, DOI 10.1007/s12035-015-9548-9
- Seminotti B, 2013, MOL GENET METAB, V108, P30, DOI 10.1016/j.ymgme.2012.11.001
- SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0
- Sweetman L, 1991, TECHNIQUES DIAGNOSTI
- Tayal V, 2008, EUR J PHARMACOL, V579, P1, DOI 10.1016/j.ejphar.2007.10.049
- Valavanidis A, 2009, J ENVIRON SCI HEAL C, V27, P120, DOI 10.1080/10590500902885684
- Zeinali M, 2017, BIOMED PHARMACOTHER, V92, P998, DOI 10.1016/j.biopha.2017.06.003